Do analysts rate SNTG or RAPP?

Rapport Therapeutics has a consensus price target of $66.11, suggesting a potential upside of 121.48%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rapport Therapeutics is more favorable than Sentage. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sentage 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rapport Therapeutics 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has stronger valuation & earnings, SNTG or RAPP?

Sentage has higher revenue and earnings than Rapport Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sentage $70K 68.80 -$2.28M N/A N/A Rapport Therapeutics N/A N/A -$111.48M -$3.04 N/A

Is SNTG or RAPP more profitable?

Sentage's return on equity of 0.00% beat Rapport Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sentage N/A N/A N/A Rapport Therapeutics N/A -29.02% -27.37%

Which has stronger valuation and earnings, RAPP or DFTX?

Definium Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rapport Therapeutics N/A N/A -$111.48M -$3.04 N/A Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A

Is RAPP or DFTX more profitable?

Rapport Therapeutics' return on equity of -29.02% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rapport Therapeutics N/A -29.02% -27.37% Definium Therapeutics N/A -84.01% -63.66%

Does the media refer more to RAPP or DFTX?

In the previous week, Rapport Therapeutics had 9 more articles in the media than Definium Therapeutics. MarketBeat recorded 10 mentions for Rapport Therapeutics and 1 mentions for Definium Therapeutics. Rapport Therapeutics' average media sentiment score of 0.36 beat Definium Therapeutics' score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Definium Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, MANE or RAPP?

Veradermics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A -$70M -$1.90 N/A Rapport Therapeutics N/A N/A -$111.48M -$3.04 N/A

Is MANE or RAPP more profitable?

Veradermics' return on equity of 0.00% beat Rapport Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Rapport Therapeutics N/A -29.02% -27.37%

Does the media prefer MANE or RAPP?

In the previous week, Rapport Therapeutics had 7 more articles in the media than Veradermics. MarketBeat recorded 10 mentions for Rapport Therapeutics and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.63 beat Rapport Therapeutics' score of 0.36 indicating that Veradermics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor INDV or RAPP?

In the previous week, Rapport Therapeutics had 8 more articles in the media than Indivior. MarketBeat recorded 10 mentions for Rapport Therapeutics and 2 mentions for Indivior. Indivior's average media sentiment score of 1.26 beat Rapport Therapeutics' score of 0.36 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor OGN or RAPP?

In the previous week, Rapport Therapeutics had 8 more articles in the media than Organon & Co.. MarketBeat recorded 10 mentions for Rapport Therapeutics and 2 mentions for Organon & Co.. Rapport Therapeutics' average media sentiment score of 0.36 beat Organon & Co.'s score of 0.32 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rapport Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Rapport Therapeutics (RAPP) Competitors

$30.63 +0.78 (+2.62%)

Closing price 03:59 PM Eastern

Extended Trading

$30.68 +0.05 (+0.17%)

As of 04:04 PM Eastern

Compare

RAPP vs. SNTG, DFTX, MANE, INDV, and OGN

Should you buy Rapport Therapeutics stock or one of its competitors? Rapport Therapeutics's main competitors and comparable companies include Sentage (SNTG), Definium Therapeutics (DFTX), Veradermics (MANE), Indivior (INDV), and Organon & Co. (OGN). Companies are selected based on similarities in market, industry, and size.

How does Rapport Therapeutics compare to Sentage?

Sentage (NASDAQ:SNTG) and Rapport Therapeutics (NASDAQ:RAPP) are related small-cap companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Sentage has higher revenue and earnings than Rapport Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sentage	$70K	68.80	-$2.28M	N/A	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A

In the previous week, Rapport Therapeutics had 10 more articles in the media than Sentage. MarketBeat recorded 10 mentions for Rapport Therapeutics and 0 mentions for Sentage. Rapport Therapeutics' average media sentiment score of 0.36 beat Sentage's score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sentage	Neutral
Rapport Therapeutics	Neutral

Sentage has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Rapport Therapeutics has a consensus price target of $66.11, suggesting a potential upside of 121.48%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rapport Therapeutics is more favorable than Sentage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sentage	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

0.1% of Sentage shares are held by institutional investors. 62.4% of Sentage shares are held by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sentage's return on equity of 0.00% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sentage	N/A	N/A	N/A
Rapport Therapeutics	N/A	-29.02%	-27.37%

Summary

Sentage beats Rapport Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Rapport Therapeutics compare to Definium Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Rapport Therapeutics' return on equity of -29.02% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-29.02%	-27.37%
Definium Therapeutics	N/A	-84.01%	-63.66%

Rapport Therapeutics currently has a consensus price target of $66.11, suggesting a potential upside of 121.48%. Definium Therapeutics has a consensus price target of $64.88, suggesting a potential upside of 89.80%. Given Rapport Therapeutics' higher probable upside, research analysts clearly believe Rapport Therapeutics is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00

Rapport Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market.

In the previous week, Rapport Therapeutics had 9 more articles in the media than Definium Therapeutics. MarketBeat recorded 10 mentions for Rapport Therapeutics and 1 mentions for Definium Therapeutics. Rapport Therapeutics' average media sentiment score of 0.36 beat Definium Therapeutics' score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Definium Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

27.9% of Definium Therapeutics shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Definium Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

Summary

Rapport Therapeutics beats Definium Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Rapport Therapeutics compare to Veradermics?

Veradermics (NYSE:MANE) and Rapport Therapeutics (NASDAQ:RAPP) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

In the previous week, Rapport Therapeutics had 7 more articles in the media than Veradermics. MarketBeat recorded 10 mentions for Rapport Therapeutics and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.63 beat Rapport Therapeutics' score of 0.36 indicating that Veradermics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veradermics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A

Veradermics' return on equity of 0.00% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Rapport Therapeutics	N/A	-29.02%	-27.37%

Veradermics currently has a consensus price target of $153.00, suggesting a potential upside of 20.81%. Rapport Therapeutics has a consensus price target of $66.11, suggesting a potential upside of 121.48%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rapport Therapeutics is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Rapport Therapeutics beats Veradermics on 6 of the 11 factors compared between the two stocks.

How does Rapport Therapeutics compare to Indivior?

Indivior (NASDAQ:INDV) and Rapport Therapeutics (NASDAQ:RAPP) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Rapport Therapeutics had 8 more articles in the media than Indivior. MarketBeat recorded 10 mentions for Rapport Therapeutics and 2 mentions for Indivior. Indivior's average media sentiment score of 1.26 beat Rapport Therapeutics' score of 0.36 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Indivior has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Indivior presently has a consensus target price of $45.17, suggesting a potential upside of 27.41%. Rapport Therapeutics has a consensus target price of $66.11, suggesting a potential upside of 121.48%. Given Rapport Therapeutics' higher possible upside, analysts plainly believe Rapport Therapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Indivior has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.38	$210M	$2.79	12.71
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A

60.3% of Indivior shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Indivior has a net margin of 26.65% compared to Rapport Therapeutics' net margin of 0.00%. Rapport Therapeutics' return on equity of -29.02% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Rapport Therapeutics	N/A	-29.02%	-27.37%

Summary

Indivior beats Rapport Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rapport Therapeutics compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Rapport Therapeutics (NASDAQ:RAPP) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Organon & Co. has a net margin of 3.41% compared to Rapport Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Rapport Therapeutics	N/A	-29.02%	-27.37%

77.4% of Organon & Co. shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Organon & Co. has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

In the previous week, Rapport Therapeutics had 8 more articles in the media than Organon & Co.. MarketBeat recorded 10 mentions for Rapport Therapeutics and 2 mentions for Organon & Co.. Rapport Therapeutics' average media sentiment score of 0.36 beat Organon & Co.'s score of 0.32 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rapport Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organon & Co. has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.89
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 17.25%. Rapport Therapeutics has a consensus target price of $66.11, suggesting a potential upside of 121.48%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rapport Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Organon & Co. beats Rapport Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Rapport Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RAPP vs. The Competition

Export

Metric	Rapport Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.47B	$12.35B	$7.19B	$13.28B
Dividend Yield	N/A	2.65%	2.53%	16.36%
P/E Ratio	-10.08	795.15	274.47	26.16
Price / Sales	73.49	835.72	585.00	81.25
Price / Cash	N/A	86.17	76.82	53.72
Price / Book	3.01	10.71	11.21	6.34
Net Income	-$111.48M	$2.84B	$3.50B	$381.90M
7 Day Performance	-4.78%	-0.96%	-0.83%	-1.36%
1 Month Performance	-30.19%	-5.81%	-5.42%	-4.29%
1 Year Performance	14.56%	-5.29%	4.36%	-0.33%

Rapport Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RAPP Rapport Therapeutics	2.7346 of 5 stars	$30.63 +2.6%	$66.11 +115.8%	+10.3%	$1.47B	$20M	N/A	84	Analyst Forecast Insider Trade
SNTG Sentage	0.8154 of 5 stars	$1.75 +1.7%	N/A	-44.2%	$4.83M	$70K	N/A	7	Positive News Gap Down
DFTX Definium Therapeutics	2.8656 of 5 stars	$38.21 -0.5%	$64.88 +69.8%	+166.8%	$5.16B	N/A	N/A	40	Analyst Forecast
MANE Veradermics	1.9147 of 5 stars	$117.50 +2.2%	$153.00 +30.2%	N/A	$4.80B	N/A	N/A	21	News Coverage
INDV Indivior	4.3731 of 5 stars	$36.59 -0.8%	$45.17 +23.4%	+47.3%	$4.35B	$1.24B	10.10	838	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RAPP) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rapport Therapeutics (RAPP) Competitors

RAPP vs. SNTG, DFTX, MANE, INDV, and OGN

How does Rapport Therapeutics compare to Sentage?

Summary

How does Rapport Therapeutics compare to Definium Therapeutics?

Summary

How does Rapport Therapeutics compare to Veradermics?

Summary

How does Rapport Therapeutics compare to Indivior?

Summary

How does Rapport Therapeutics compare to Organon & Co.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rapport Therapeutics (RAPP) Competitors

RAPP vs. SNTG, DFTX, MANE, INDV, and OGN

How does Rapport Therapeutics compare to Sentage?

Which has stronger valuation & earnings, SNTG or RAPP?

Does the media refer more to SNTG or RAPP?

Which has more risk & volatility, SNTG or RAPP?

Do analysts rate SNTG or RAPP?

Do institutionals & insiders hold more shares of SNTG or RAPP?

Is SNTG or RAPP more profitable?

Summary

How does Rapport Therapeutics compare to Definium Therapeutics?

Is RAPP or DFTX more profitable?

Do analysts rate RAPP or DFTX?

Which has more risk & volatility, RAPP or DFTX?

Does the media refer more to RAPP or DFTX?

Do insiders & institutionals have more ownership in RAPP or DFTX?

Which has stronger valuation and earnings, RAPP or DFTX?

Summary

How does Rapport Therapeutics compare to Veradermics?

Does the media prefer MANE or RAPP?

Which has preferable earnings & valuation, MANE or RAPP?

Is MANE or RAPP more profitable?

Do analysts prefer MANE or RAPP?

Summary

How does Rapport Therapeutics compare to Indivior?

Does the media favor INDV or RAPP?

Which has more risk and volatility, INDV or RAPP?

Do analysts prefer INDV or RAPP?

Which has stronger valuation & earnings, INDV or RAPP?

Do insiders & institutionals have more ownership in INDV or RAPP?

Is INDV or RAPP more profitable?

Summary

How does Rapport Therapeutics compare to Organon & Co.?

Is OGN or RAPP more profitable?

Do insiders & institutionals have more ownership in OGN or RAPP?

Which has more volatility and risk, OGN or RAPP?

Does the media favor OGN or RAPP?

Which has higher valuation & earnings, OGN or RAPP?

Do analysts recommend OGN or RAPP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools